Literature DB >> 11196177

Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins.

C Lanari1, I Lüthy, C A Lamb, V Fabris, E Pagano, L A Helguero, N Sanjuan, S Merani, A A Molinolo.   

Abstract

We have developed an experimental model of mammary carcinogenesis in which the administration of medroxyprogesterone acetate (MPA) to female BALB/c mice induces progestin-dependent ductal metastatic mammary tumors with high levels of estrogen receptor (ER) and progesterone receptor (PR). Through selective transplants in untreated mice, we have obtained progestin-independent variants, still expressing high levels of ER and PR. Primary cultures of the MPA-induced carcinomas C4-HD and C7-HI were set up, and after 3-4 months, several different cell lines were obtained. Four of these, MC4-L1, MC4-L2, MC4-L3, and MC4-L5 were established from C4-HD and a fifth, MC7-L1, from C7-HI. All cells were of epithelial origin, as demonstrated by electron microscopy and by immunocytochemical identification of cytokeratin and cadherin. In vitro MC4-L1, MC4-L3, and MC4-L5 showed a typical epithelial morphology; when transplanted in vivo, they originated metastatic carcinomas with different degrees of differentiation. MC4-L2 and MC7-L1 deviated from the standard epithelial picture; they disclosed a spindle-shaped morphology in vitro and in vivo gave rise to a biphasic spindle cell/tubular carcinoma and an anaplastic carcinoma, respectively; both lines gave rise to metastases. This differential morphology correlated with a higher degree of aggressiveness, as compared with MC4-L1, MC4-L3, and MC4-L5. ERs and PRs were detected by binding, immunocytochemistry, and Western blot. In vitro, MC4-L2 and MC7-L1 were stimulated by MPA (nM to microM) and 17beta-estradiol (nM and 10 nM); no significant stimulation was observed in MC4-L1, MC4-L3, and MC4-L5 under the same experimental conditions. In vivo, MPA significantly stimulated tumor growth in all epithelioid lines but not in MC4-L2 and MC7-L1. A progestin-dependent growth pattern was confirmed for MC4-L1, MC4-L3, and MC4-L5 in successive transplants, whereas MC4-L2 and MC7-L1 behaved as progestin independent. This is the first description of mouse mammary carcinoma cell lines expressing ER and PR. The different in vitro hormone responses as compared with in vivo and the differential effects of 17beta-estradiol in the parental tumors and in cell lines render these lines useful tools for the in vitro and in vivo study of hormone regulation of tumor growth and metastases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11196177

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  In Vitro and In Vivo Efficacy of the Monocarboxylate Transporter 1 Inhibitor AR-C155858 in the Murine 4T1 Breast Cancer Tumor Model.

Authors:  Xiaowen Guan; Mark A Bryniarski; Marilyn E Morris
Journal:  AAPS J       Date:  2018-11-05       Impact factor: 4.009

2.  Exercise-induced changes in tumour LDH-B and MCT1 expression are modulated by oestrogen-related receptor alpha in breast cancer-bearing BALB/c mice.

Authors:  Malihe Aveseh; Rohollah Nikooie; Mohsen Aminaie
Journal:  J Physiol       Date:  2015-05-18       Impact factor: 5.182

3.  HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer.

Authors:  Debarati Banik; Satish Noonepalle; Melissa Hadley; Erica Palmer; Maria Gracia-Hernandez; Christian Zevallos-Delgado; Namratta Manhas; Hayk Simonyan; Colin N Young; Anastas Popratiloff; Katherine B Chiappinelli; Rohan Fernandes; Eduardo M Sotomayor; Alejandro Villagra
Journal:  Cancer Res       Date:  2020-06-30       Impact factor: 12.701

4.  Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation.

Authors:  C Pérez Piñero; A Bruzzone; M G Sarappa; L F Castillo; I A Lüthy
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

5.  [11C] acetoacetate utilization by breast and prostate tumors: a PET and biodistribution study in mice.

Authors:  Simon Authier; Sébastien Tremblay; Véronique Dumulon; Céléna Dubuc; René Ouellet; Roger Lecomte; Stephen C Cunnane; François Bénard
Journal:  Mol Imaging Biol       Date:  2008-05-03       Impact factor: 3.488

6.  Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.

Authors:  Michel Paquette; Serge Phoenix; René Ouellet; Réjean Langlois; Johan E van Lier; Eric E Turcotte; Francois Bénard; Roger Lecomte
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

7.  Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.

Authors:  Maria Laura Polo; Maria Victoria Arnoni; Marina Riggio; Victoria Wargon; Claudia Lanari; Virginia Novaro
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

8.  Isolation and molecular characterization of a mouse renal microvascular endothelial cell line.

Authors:  Silvina Gazzaniga; Lorena González; Alberto Mantovani; Annunciata Vecchi; Rosa Wainstok
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Mar-Apr       Impact factor: 2.416

9.  [18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice.

Authors:  François Bénard; Naseem Ahmed; Jean-Mathieu Beauregard; Jacques Rousseau; Antonio Aliaga; Céléna Dubuc; Etienne Croteau; Johan E van Lier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-13       Impact factor: 9.236

10.  The effect of thrombospondin-1 on breast cancer metastasis.

Authors:  Karen O Yee; Caitlin M Connolly; Mark Duquette; Shideh Kazerounian; Raymond Washington; Jack Lawler
Journal:  Breast Cancer Res Treat       Date:  2008-04-13       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.